

Characteristic	STEAP1 expression		p	STEAP2 expression		p	STEAP3 expression		p	STEAP4 expression		p
	Low (n=187)	High (n=188)		Low (n=187)	High (n=188)		Low (n=187)	High (n=188)		Low (n=187)	High (n=188)	
n												
Age, n (%)			0.106			1			0.27			0.27
<=65	90 (24.3%)	74 (19.9%)		82 (22.1%)	82 (22.1%)		88 (23.7%)	76 (20.5%)		76 (20.5%)	88 (23.7%)	
>65	95 (25.6%)	112 (30.2%)		103 (27.8%)	104 (28%)		98 (26.4%)	109 (29.4%)		109 (29.4%)	98 (26.4%)	
Gender, n (%)			0.776			0.945			0.945			0.718
Female	65 (17.3%)	69 (18.4%)		66 (17.6%)	68 (18.1%)		66 (17.6%)	68 (18.1%)		69 (18.4%)	65 (17.3%)	
Male	122 (32.5%)	119 (31.7%)		121 (32.3%)	120 (32%)		121 (32.3%)	120 (32%)		118 (31.5%)	123 (32.8%)	
Race, n (%)			0.306			0.004*			0.023*			0.138
Asian	42 (13%)	32 (9.9%)		46 (14.2%)	28 (8.7%)		47 (14.6%)	27 (8.4%)		42 (13%)	32 (9.9%)	
Black or African American	5 (1.5%)	6 (1.9%)		7 (2.2%)	4 (1.2%)		3 (0.9%)	8 (2.5%)		7 (2.2%)	4 (1.2%)	
White	111 (34.4%)	127 (39.3%)		98 (30.3%)	140 (43.3%)		116 (35.9%)	122 (37.8%)		108 (33.4%)	130 (40.2%)	
T stage, n (%)			0.797			0.038*			0.115			0.719
T1	10 (2.7%)	9 (2.5%)		13 (3.5%)	6 (1.6%)		7 (1.9%)	12 (3.3%)		11 (3%)	8 (2.2%)	
T2	43 (11.7%)	37 (10.1%)		46 (12.5%)	34 (9.3%)		47 (12.8%)	33 (9%)		44 (12%)	36 (9.8%)	
T3	80 (21.8%)	88 (24%)		86 (23.4%)	82 (22.3%)		87 (23.7%)	81 (22.1%)		82 (22.3%)	86 (23.4%)	
T4	52 (14.2%)	48 (13.1%)		40 (10.9%)	60 (16.3%)		43 (11.7%)	57 (15.5%)		49 (13.4%)	51 (13.9%)	
N stage, n (%)			0.631			0.525			0.402			0.351
N0	50 (14%)	61 (17.1%)		61 (17.1%)	50 (14%)		58 (16.2%)	53 (14.8%)		61 (17.1%)	50 (14%)	
N1	49 (13.7%)	48 (13.4%)		49 (13.7%)	48 (13.4%)		49 (13.7%)	48 (13.4%)		45 (12.6%)	52 (14.6%)	
N2	41 (11.5%)	34 (9.5%)		34 (9.5%)	41 (11.5%)		39 (10.9%)	36 (10.1%)		40 (11.2%)	35 (9.8%)	
N3	37 (10.4%)	37 (10.4%)		34 (9.5%)	40 (11.2%)		30 (8.4%)	44 (12.3%)		32 (9%)	42 (11.8%)	
M stage, n (%)			0.965			0.689			0.398			0.398
M0	167 (47%)	163 (45.9%)		164 (46.2%)	166 (46.8%)		168 (47.3%)	162 (45.6%)		168 (47.3%)	162 (45.6%)	
M1	12 (3.4%)	13 (3.7%)		14 (3.9%)	11 (3.1%)		10 (2.8%)	15 (4.2%)		10 (2.8%)	15 (4.2%)	
Pathologic stage, n (%)			0.731			0.002*			0.046*			0.631
Stage I	28 (8%)	25 (7.1%)		33 (9.4%)	20 (5.7%)		29 (8.2%)	24 (6.8%)		29 (8.2%)	24 (6.8%)	
Stage II	54 (15.3%)	57 (16.2%)		60 (17%)	51 (14.5%)		53 (15.1%)	58 (16.5%)		61 (17.3%)	50 (14.2%)	
Stage III	73 (20.7%)	77 (21.9%)		86 (23.9%)	91 (25.9%)		80 (22.7%)	70 (19.9%)		72 (20.5%)	78 (22.4%)	
Stage IV	22 (6.2%)	16 (4.5%)		25 (7.1%)	13 (3.7%)		11 (3.1%)	27 (7.7%)		18 (5.1%)	20 (5.7%)	
Histologic grade, n (%)			0.04*			0.053			0.001*			0.957
G1	5 (1.4%)	5 (1.4%)		5 (1.4%)	5 (1.4%)		7 (1.9%)	3 (0.8%)		5 (1.4%)	5 (1.4%)	
G2	81 (22.1%)	56 (15.3%)		80 (21.9%)	57 (15.6%)		52 (14.2%)	85 (23.2%)		70 (19.1%)	67 (18.3%)	
G3	99 (27%)	120 (32.8%)		99 (27%)	120 (32.8%)		124 (33.9%)	95 (26%)		109 (29.8%)	110 (30.1%)	
Histological type, n (%)			0.679			0.343			0.003*			0.206
Diffuse Type	32 (8.6%)	31 (8.3%)		27 (7.2%)	36 (9.6%)		43 (11.5%)	20 (5.3%)		28 (7.5%)	35 (9.4%)	
Mucinous Type	11 (2.9%)	8 (2.1%)		11 (2.9%)	8 (2.1%)		9 (2.4%)	10 (2.7%)		5 (1.3%)	14 (3.7%)	
Not Otherwise Specified	102 (27.3%)	105 (28.1%)		100 (26.7%)	107 (28.6%)		94 (25.1%)	113 (30.2%)		106 (28.3%)	101 (27%)	
Papillary Type	3 (0.8%)	2 (0.5%)		4 (1.1%)	1 (0.3%)		1 (0.3%)	4 (1.1%)		3 (0.8%)	2 (0.5%)	
Signet Ring Type	3 (0.8%)	8 (2.1%)		5 (1.3%)	6 (1.6%)		9 (2.4%)	2 (0.5%)		5 (1.3%)	6 (1.6%)	
Tubular Type	36 (9.6%)	33 (8.8%)		40 (10.7%)	29 (7.8%)		30 (8%)	39 (10.4%)		40 (10.7%)	29 (7.8%)	
Residual tumor, n (%)			0.865			0.835			0.075*			0.707
R0	149 (45.3%)	149 (45.3%)		146 (44.4%)	152 (46.2%)		150 (45.6%)	148 (44%)		152 (46.2%)	146 (44.4%)	
R1	8 (2.4%)	7 (2.1%)		7 (2.1%)	8 (2.4%)		4 (1.2%)	11 (3.3%)		6 (1.8%)	9 (2.7%)	
R2	9 (2.7%)	7 (2.1%)		9 (2.7%)	7 (2.1%)		5 (1.5%)	11 (3.3%)		8 (2.4%)	8 (2.4%)	
Anatomic neoplasm subdivision, n (%)			0.977			0.582			0.948			0.099
Antrum/Distal	73 (20.2%)	65 (18%)		77 (21.3%)	61 (16.9%)		68 (18.8%)	70 (19.4%)		70 (19.4%)	68 (18.8%)	
Cardia/Proximal	23 (6.4%)	25 (6.9%)		25 (6.9%)	23 (6.4%)		26 (7.2%)	22 (6.1%)		22 (6.1%)	26 (7.2%)	
Fundus/Body	66 (18.3%)	64 (17.7%)		60 (16.6%)	70 (19.4%)		62 (17.2%)	68 (18.8%)		73 (20.2%)	57 (15.8%)	
Gastroesophageal Junction	20 (5.5%)	21 (5.8%)		19 (5.3%)	22 (6.1%)		19 (5.3%)	22 (6.1%)		13 (3.6%)	28 (7.8%)	
Other	2 (0.6%)	2 (0.6%)		2 (0.6%)	2 (0.6%)		2 (0.6%)	2 (0.6%)		2 (0.6%)	2 (0.6%)	
Reflux history, n (%)			0.897			0.872			0.115			0.176
No	90 (42.1%)	85 (39.7%)		86 (40.2%)	89 (41.6%)		85 (39.7%)	90 (42.1%)		84 (39.3%)	91 (42.5%)	
Yes	19 (8.9%)	20 (9.3%)		18 (8.4%)	21 (9.8%)		25 (11.7%)	14 (6.5%)		24 (11.2%)	15 (7%)	
Antireflux treatment, n (%)			1			0.515			0.02*			0.307
No	67 (37.4%)	75 (41.9%)		62 (34.6%)	80 (44.7%)		63 (35.2%)	79 (44.1%)		61 (34.1%)	81 (45.3%)	
Yes	18 (10.1%)	19 (10.6%)		19 (10.6%)	18 (10.1%)		25 (14%)	12 (6.7%)		20 (11.2%)	17 (9.5%)	
H pylori infection, n (%)			0.824			0.243			0.618			1
No	73 (44.8%)	72 (44.2%)		74 (45.4%)	71 (43.6%)		67 (41.1%)	78 (47.9%)		81 (49.7%)	64 (39.3%)	
Yes	8 (4.9%)	10 (6.1%)		6 (3.7%)	12 (7.4%)		10 (6.1%)	8 (4.9%)		10 (6.1%)	8 (4.9%)	
Barretts esophagus, n (%)			0.157			0.157			0.284			0.419
No	98 (47.1%)	95 (45.7%)		98 (47.1%)	95 (45.7%)		94 (45.2%)	99 (47.6%)		105 (50.5%)	88 (42.3%)	
Yes	11 (5.3%)	4 (1.9%)		11 (5.3%)	4 (1.9%)		10 (4.8%)	5 (2.4%)		6 (2.9%)	9 (4.3%)	
Primary therapy outcome, n (%)			0.968			0.15			0.605			0.803
PD	34 (10.7%)	31 (9.8%)		40 (12.6%)	25 (7.9%)		34 (10.7%)	31 (9.8%)		30 (9.5%)	35 (11%)	
SD	8 (2.5%)	9 (2.8%)		9 (2.8%)	8 (2.5%)		6 (1.9%)	11 (3.5%)		9 (2.8%)	8 (2.5%)	
PR	2 (0.6%)	2 (0.6%)		2 (0.6%)	2 (0.6%)		2 (0.6%)	2 (0.6%)		1 (0.3%)	3 (0.9%)	
CR	118 (37.2%)	113 (35.6%)		106 (33.4%)	125 (39.4%)		119 (37.5%)	112 (35.3%)		114 (36%)	117 (36.9%)	
OS event, n (%)			0.309			0.553			0.219			0.15
Alive	119 (31.7%)	109 (29.1%)		117 (31.2%)	111 (29.6%)		120 (32%)	108 (28.8%)		121 (32.3%)	107 (28.5%)	
Dead	68 (18.1%)	79 (21.1%)		70 (18.7%)	77 (20.5%)		67 (17.9%)	80 (21.3%)		66 (17.6%)	81 (21.6%)	
DSS event, n (%)			1			0.672			0.5			0.025*
Alive	134 (37.9%)	129 (36.4%)		130 (36.7%)	133 (37.6%)		137 (38.7%)	126 (35.6%)		139 (39.3%)	124 (35%)	
Dead	47 (13.3%)	44 (12.4%)		48 (13.6%)	43 (12.1%)		43 (12.1%)	48 (13.6%)		35 (9.9%)	56 (15.8%)	
PFI event, n (%)			0.558			0.214			0.341			0.164
Alive	122 (32.5%)	129 (34.4%)		119 (31.7%)	132 (35.2%)		130 (34.7%)	121 (32.3%)		132 (35.2%)	119 (31.7%)	
Dead	65 (17.3%)	59 (15.7%)		68 (18.1%)	56 (14.9%)		57 (15.2%)	67 (17.9%)		55 (14.7%)	69 (18.4%)	

Table 1:Relationship between STRIDE family member expression and clinicopathological characteristics in gastric cancer cohorts